About HLB
HLB is a company based in Ulsan (South Korea) founded in 1985. The company has 168 employees as of December 31, 2024. HLB has completed 2 acquisitions, including Anygen and GtreeBNT. HLB offers products and services including Rivoceranib and Other Therapies.
- Headquarter Ulsan, South Korea
- Employees 168 as on 31 Dec, 2024
- Stage Public
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Hlb Co., Ltd.
-
Annual Revenue
$46.19 M (USD)58.8as on Dec 31, 2024
-
Net Profit
-$62.36 M (USD)50.96as on Dec 31, 2024
-
EBITDA
-$76.23 M (USD)-5.74as on Dec 31, 2024
-
Latest Funding Round
- Investors
-
Employee Count
168
as on Dec 31, 2024
-
Investments & Acquisitions
Anygen
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of HLB
HLB is a publicly listed company on the KRX with ticker symbol 028300 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of HLB
HLB offers a comprehensive portfolio of products and services, including Rivoceranib and Other Therapies.
Rivoceranib is positioned as a targeted therapy for various cancers, including liver and lung cancers, that is developed to meet specific medical needs
Other therapies such as CAR-T and immune therapies are offered under HLB's pharmaceutical portfolio to address a range of oncology applications
Funding Insights of HLB
- Total Funding Total Funding
- Total Rounds 1
- Last Round Last Round
- First Round First Round
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2017 | Amount | Post-IPO - HLB | Valuation |
investors |
Investors in HLB
HLB has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include E&Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location |
Financial Statements - HLB
Hlb Comparisons
Competitors of HLB
Latest news on Hlb
Frequently Asked Questions about HLB
HLB was founded in 1985 and raised its 1st funding round 32 years after it was founded.
HLB is headquartered in Ulsan, South Korea.
Jin Yang Gon is the current CEO of HLB.
As of Dec 31, 2024, the latest employee count at HLB is 168.
Annual revenue of HLB is $46.19M as on Dec 31, 2024.
HLB, established in 1985 and currently in Public stage, focuses on manufacturer of marine composite materials. Manufacturer of marine composite materials. Adapting to market demands with innovation. It continues to evolve, meeting industry challenges with strategic approaches and commitment to quality.
HLB offers Rivoceranib and Other Therapies.
Yes, HLB is publicly traded on KRX under the ticker symbol 028300.
HLB has 1 investor. Key investors include E&Investment.
The ticker symbol of HLB is 028300 on KRX.